Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20373238 | 0.81 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| SCHEMBL12807 | 0.78 | GAA (0.65) | GAACA1CA2CA12CA3 | |
| SCHEMBL28182477 | 0.78 | GAA (0.65) | GAACA1CA2CA12CA3 | |
| SCHEMBL2290762 | 0.77 | PTGS2 (0.48) | CA1CA2ALDH1A1MMP1MMP2 | |
| SCHEMBL17642663 | 0.77 | CA1 (0.46) | CA1CA2CA12CA9MMP1 | |
| SCHEMBL23145865 | 0.77 | ENPP2 (0.41) | GAACA1CA2CA12CA3 | |
| SCHEMBL3929345 | 0.77 | TSHR (0.56) | GAACA1CA2CA12CA6 | |
| SCHEMBL9628601 | 0.77 | CA2 (0.52) | GAACA1CA2CA12CA9 | |
| SCHEMBL11586425 | 0.77 | GAA (0.56) | GAACA1CA2CA12CA3 | |
| SCHEMBL19483507 | 0.77 | GAA (0.56) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112390697-B | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2023-03-10 | — | — | CN | claimed |
| CN-112390697-A | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2021-02-23 | — | — | CN | claimed |
| WO-2025073057-A1 | METHODS FOR PREPARING SULFILIMINES AND SULFOXIMINES FROM THIOETHERS USING O-(DIPHENYLPHOSPHINYL)HYDROXYL AMINE (DPPH), AND AMATOXIN ANALOGS PREPARED FROM SUCH METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-04-10 | — | — | WO | disclosed |
| CN-117305865-A | Electrochemical method for preparing N-aroyl sulfoxide imine compound | 桂林理工大学 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023081841-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-112390697-B | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-114920680-A | Synthetic method for N-arylation of NH-sulfoximine under aqueous phase catalysis | 新乡市润宇新材料科技有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022135365-A1 | DISUBSTITUTED CYCLOPENTANE KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
| WO-2021225969-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
| US-20060217353-A1 | 24-sulfoximine vitamin D3 compounds | CYTOCHROMA INC. (CA) | 2006-09-28 | — | — | US | disclosed |
| US-7101865-B2 | 24-sulfoximine vitamin D3 compounds | CYTOCHROMA INC. (CA) | 2006-09-05 | — | — | US | disclosed |
| EP-1511725-A1 | 24-SULFOXIMINE VITAMIN D sb 3 /sb COMPOUNDS | Johns Hopkins University (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040038949-A1 | 24-sulfoximine vitamin D3 compounds | JOHNS HOPKINS UNIVERSITY | 2004-02-26 | — | — | US | disclosed |
| WO-2003106411-A1 | 24-SULFOXIMINE VITAMIN D3 COMPOUNDS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-4556413-A | POSTEMERGENCE AND PREEMERGENCE HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0109575-A2 | Benzoic-acid derivatives, process and means for its production | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038949-A1 | 24-sulfoximine vitamin D3 compounds | CYP24A1, CYP2R1, CYP27B1 | GAA 2327/4885CA1 3379/4885CA2 2871/4885 |
| US-20060217353-A1 | 24-sulfoximine vitamin D3 compounds | CYP24A1, CYP2R1, CYP27B1 | GAA 2265/4885CA1 3533/4885CA2 3149/4885 |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | IFNG, TPMT, IRF3 | GAA 1574/4885CA1 3700/4885CA2 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.